Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.69 |
| ▸ | MAPK13 | O15264 | 11/20 | 0.69 |
| ▸ | MAPK12 | P53778 | 11/20 | 0.69 |
| ▸ | MAPK11 | Q15759 | 11/20 | 0.69 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | CETP | P11597 | 1/20 | 0.46 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.45 |
| ▸ | EP300 | Q09472 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6813199 | 0.90 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11P2RX7 | |
| SCHEMBL6817091 | 0.90 | MAPK14 (0.64) | MAPK14MAPK13MAPK12MAPK11EP300 | |
| SCHEMBL6813046 | 0.89 | MAPK14 (0.70) | MAPK14MAPK13MAPK12MAPK11HDAC3 | |
| SCHEMBL6095607 | 0.87 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6095615 | 0.87 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6394634 | 0.85 | MAPK14 (0.80) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6821214 | 0.85 | MAPK14 (0.77) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6812883 | 0.85 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6400648 | 0.85 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6817276 | 0.84 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1210320-B1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA | LEO PHARMA AS (DK) | 2004-09-29 | — | — | EP | claimed |
| US-6566554-B1 | Including amino benzothiophenones; useful for treatment of inflammatory diseases in which the production of cytokines is involved in the pathogenesis | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2003-05-20 | — | — | US | claimed |
| US-8293772-B2 | Triazole substituted aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2012-10-23 | — | — | US | disclosed |
| EP-1658263-B9 | NOVEL AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA AS (DK) | 2011-11-09 | — | — | EP | disclosed |
| US-7977387-B2 | Aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2011-07-12 | — | — | US | disclosed |
| EP-1658263-B1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA AS (DK) | 2010-06-02 | — | — | EP | disclosed |
| EP-1828148-B1 | TRIAZOLE SUBSTITUTED AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA AS (DK) | 2010-01-20 | — | — | EP | disclosed |
| EP-1828148-A1 | TRIAZOLE SUBSTITUTED AMINOBENZOPHENONE COMPOUNDS | Leo Pharma A/S (DK) | 2007-09-05 | — | — | EP | disclosed |
| US-20060166990-A1 | Novel aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2006-07-27 | — | — | US | disclosed |
| WO-2006063585-A1 | TRIAZOLE SUBSTITUTED AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA A/S (DK) | 2006-06-22 | — | — | WO | disclosed |
| US-20060128766-A1 | Triazole substituted aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2006-06-15 | — | — | US | disclosed |
| EP-1658263-A1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | Leo Pharma A/S (DK) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005009940-A1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA A/S (DK) | 2005-02-03 | — | — | WO | disclosed |
| EP-1210320-B1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA | LEO PHARMA AS (DK) | 2004-09-29 | — | — | EP | disclosed |
| US-6566554-B1 | Including amino benzothiophenones; useful for treatment of inflammatory diseases in which the production of cytokines is involved in the pathogenesis | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2003-05-20 | — | — | US | disclosed |
| EP-1210320-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001005746-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128766-A1 | Triazole substituted aminobenzophenone compounds | NFKBIA, UACA, CYP1B1 | MAPK14 1089/4885MAPK13 1436/4885MAPK12 1829/4885 |
| US-20060166990-A1 | Novel aminobenzophenone compounds | NFKBIA, UACA, ALDH7A1 | MAPK14 697/4885MAPK13 1063/4885MAPK12 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.